FMP

FMP

Enter

CTMX - CytomX Therapeutics,...

Financial Summary of CytomX Therapeutics, Inc.(CTMX), CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United St

photo-url-https://financialmodelingprep.com/image-stock/CTMX.png

CytomX Therapeutics, Inc.

CTMX

NASDAQ

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

1.97 USD

-0.18 (-9.14%)

About

ceo

Dr. Sean A. McCarthy DPHIL

sector

Healthcare

industry

Biotechnology

website

https://www.cytomx.com

exchange

NASDAQ

Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical tri...

CIK

0001501989

ISIN

US23284F1057

CUSIP

23284F105

Address

151 Oyster Point Boulevard

Phone

650 515 3185

Country

US

Employee

120

IPO Date

Oct 8, 2015

Summary

CIK

0001501989

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

23284F105

ISIN

US23284F1057

Country

US

Price

1.97

Beta

1.02

Volume Avg.

922.78k

Market Cap

133.41M

Shares

-

52-Week

1.04-2.855

DCF

-0.04

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-197

P/B

-

Website

https://www.cytomx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CTMX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep